To include your compound in the COVID-19 Resource Center, submit it here.

Tetraphase antibiotic headed for submissions

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) rose $1.75 (25%) to $8.65 in after-hours trading on Tuesday after it said eravacycline (TP-434) met FDA's and EMA's primary

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE